control sirna with scrambled sequence Search Results


90
Ribobio co pfn1 sirna
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Pfn1 Sirna, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pmc09108340-61-0-10?v=Ribobio+co
Average 90 stars, based on 1 article reviews
pfn1 sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma negative control sirna scrambled sequence
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Negative Control Sirna Scrambled Sequence, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/10__1186_slash_1556___276x___9___587-40-7-20?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
negative control sirna scrambled sequence - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma small interfering rnas (sirnas) of circglis2 back splicing junction sequences and negative control (nc)
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Small Interfering Rnas (Sirnas) Of Circglis2 Back Splicing Junction Sequences And Negative Control (Nc), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm39370077-79-4-19?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
small interfering rnas (sirnas) of circglis2 back splicing junction sequences and negative control (nc) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirna targeting sequence: negative control, 50-ttctccgaacgtgtcacgt-30
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Sirna Targeting Sequence: Negative Control, 50 Ttctccgaacgtgtcacgt 30, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm39413734-196-48-49?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
sirna targeting sequence: negative control, 50-ttctccgaacgtgtcacgt-30 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma scrambled sirna sequences for erk
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Scrambled Sirna Sequences For Erk, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pmc06360289-89-2-6?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
scrambled sirna sequences for erk - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirna targeting foxn3
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Sirna Targeting Foxn3, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm40307279-75-14-27?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
sirna targeting foxn3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirnas targeting the back-splice junction sequences of circift80 and the respective negative-control oligonucleotides
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Sirnas Targeting The Back Splice Junction Sequences Of Circift80 And The Respective Negative Control Oligonucleotides, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pmc06819894__mmc2-197-8-17?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
sirnas targeting the back-splice junction sequences of circift80 and the respective negative-control oligonucleotides - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma scrambled rna sequence and dancr-targeting sirnas
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Scrambled Rna Sequence And Dancr Targeting Sirnas, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/10__2147_slash_ott__s196851-40-10-15?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
scrambled rna sequence and dancr-targeting sirnas - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co sirna sequences targeting cenpe and control
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Sirna Sequences Targeting Cenpe And Control, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm33862458-53-17-32?v=Ribobio+co
Average 90 stars, based on 1 article reviews
sirna sequences targeting cenpe and control - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Upstate Group Inc irs1 smartpool sirna reagent
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Irs1 Smartpool Sirna Reagent, supplied by Upstate Group Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm22664743-67-0-17?v=Upstate+Group+Inc
Average 90 stars, based on 1 article reviews
irs1 smartpool sirna reagent - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
TriLink 6-fam-labeled control (non-sequence-specific) modified hybrid sirna
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
6 Fam Labeled Control (Non Sequence Specific) Modified Hybrid Sirna, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm16409130-35-4-15?v=TriLink
Average 90 stars, based on 1 article reviews
6-fam-labeled control (non-sequence-specific) modified hybrid sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirna sequences for human fmnl2 and p27, and the negative control sirna (nc sirna)
Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of <t>ERK,</t> JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled <t>siRNA,</t> JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.
Sirna Sequences For Human Fmnl2 And P27, And The Negative Control Sirna (Nc Sirna), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+sirna+with+scrambled+sequence/pm34193109-82-7-17?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
sirna sequences for human fmnl2 and p27, and the negative control sirna (nc sirna) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


PFN1 is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Migration, In Vitro, Expressing, Staining, Knockdown, Plasmid Preparation, Over Expression, Negative Control

PFN1 could promote MVs secretion in NSCLC. (A) Heatmap of differentially expressed proteins between EV and PFN1 OE cells. (B) GO enrichment analysis of differentially expressed proteins. (C) COG/KOG analysis of differentially expressed proteins. (D) MVs extracted from EV-expressing and PFN1 -overexpressing cells, using continuous differential centrifugation, identified using transmission electron microscopy. Scale bar, 100 nm. (E,F) Flow cytometry (E) and western blotting (F) were used to quantify MVs in PFN1 -overexpressing and EV-expressing cells. ARF6 and actin were used as MV markers. (G) Expression of PFN1 and annexin A1 in lung tumor tissues detected using immunofluorescence. (H) The staining index of p-MLC on the tissue chip. ** p < 0.01. (I) Representative IHC images of p-MLC expression. (J) Spearman rank correlation analysis was used to assess the relationship between PFN1 and p-MLC expression on the tissue chip; p and r values are shown in the plot.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 could promote MVs secretion in NSCLC. (A) Heatmap of differentially expressed proteins between EV and PFN1 OE cells. (B) GO enrichment analysis of differentially expressed proteins. (C) COG/KOG analysis of differentially expressed proteins. (D) MVs extracted from EV-expressing and PFN1 -overexpressing cells, using continuous differential centrifugation, identified using transmission electron microscopy. Scale bar, 100 nm. (E,F) Flow cytometry (E) and western blotting (F) were used to quantify MVs in PFN1 -overexpressing and EV-expressing cells. ARF6 and actin were used as MV markers. (G) Expression of PFN1 and annexin A1 in lung tumor tissues detected using immunofluorescence. (H) The staining index of p-MLC on the tissue chip. ** p < 0.01. (I) Representative IHC images of p-MLC expression. (J) Spearman rank correlation analysis was used to assess the relationship between PFN1 and p-MLC expression on the tissue chip; p and r values are shown in the plot.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Expressing, Centrifugation, Transmission Assay, Electron Microscopy, Flow Cytometry, Western Blot, Immunofluorescence, Staining

MVs derived from PFN1 OE cells promote migration in NSCLC cells. (A) MVs collected from sera of patients with NSCLC quantified using flow cytometry. ** p < 0.01. (B) Protein expression of ARF6 and β-actin in MVs collected from sera of patients with NSCLC detected using western blotting. (C) Effect of PFN1 -overexpressing cell supernatants on cell migration evaluated through wound healing assays. ** p < 0.01; scale bar, 500 μm. (D) PKH67-labeled MVs taken up by H1299 cells. DAPI was used to stain the nuclei of H1299 cells. Scale bar, 500 μm. (E,F) Wound healing (E) and Transwell migration (F) assays conducted to evaluate the migration of H1299 cells after treatment with MVs derived from EV-expressing and PFN1 -overexpressing cells; ** p < 0.01; scale bar, 500 μm.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: MVs derived from PFN1 OE cells promote migration in NSCLC cells. (A) MVs collected from sera of patients with NSCLC quantified using flow cytometry. ** p < 0.01. (B) Protein expression of ARF6 and β-actin in MVs collected from sera of patients with NSCLC detected using western blotting. (C) Effect of PFN1 -overexpressing cell supernatants on cell migration evaluated through wound healing assays. ** p < 0.01; scale bar, 500 μm. (D) PKH67-labeled MVs taken up by H1299 cells. DAPI was used to stain the nuclei of H1299 cells. Scale bar, 500 μm. (E,F) Wound healing (E) and Transwell migration (F) assays conducted to evaluate the migration of H1299 cells after treatment with MVs derived from EV-expressing and PFN1 -overexpressing cells; ** p < 0.01; scale bar, 500 μm.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Derivative Assay, Migration, Flow Cytometry, Expressing, Western Blot, Labeling, Staining

PFN1 promotes in vivo NSCLC metastasis by elevating MV secretion. (A) Schematic illustration of the mouse model of metastatic tumor established to determine the role of PFN1 in tumor metastasis. (B) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing and EV-expressing cell lines. (C,D) Representative images of lung (C) and liver (D) metastases of the mouse model. The number of metastases is displayed in the right-hand side graph. * p < 0.05, ** p < 0.01. (E) Representative images of HE-stained lung tissues of the mouse model. (F) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (G) Representative images of HE-stained liver tissues of the mouse model. (H) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (I) Body weight changes in mice after intracardiac injection of H1299 cells and MVs. (J) Representative images of lung metastases of the mouse model. The number of metastases is shown in the bottom graph. * p < 0.05. (K) Representative images of HE-stained lung tissues of the mouse model. (L) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph; * p < 0.05.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 promotes in vivo NSCLC metastasis by elevating MV secretion. (A) Schematic illustration of the mouse model of metastatic tumor established to determine the role of PFN1 in tumor metastasis. (B) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing and EV-expressing cell lines. (C,D) Representative images of lung (C) and liver (D) metastases of the mouse model. The number of metastases is displayed in the right-hand side graph. * p < 0.05, ** p < 0.01. (E) Representative images of HE-stained lung tissues of the mouse model. (F) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (G) Representative images of HE-stained liver tissues of the mouse model. (H) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (I) Body weight changes in mice after intracardiac injection of H1299 cells and MVs. (J) Representative images of lung metastases of the mouse model. The number of metastases is shown in the bottom graph. * p < 0.05. (K) Representative images of HE-stained lung tissues of the mouse model. (L) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph; * p < 0.05.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: In Vivo, Injection, Expressing, Staining

Mechanisms underlying the promotion of MLC phosphorylation by PFN1. (A,B) Protein expression after PFN1 overexpression (A) and knockdown (B) measured using western blotting. (C) Protein expression in PFN1 mutants measured using western blotting. (D) PFN1 interactions with ROCK1/2 confirmed using co-IP. (E) Protein expression after treatment with Y27632 (10 µM) measured using western blotting. (F) Effect of PFN1 on ROCK1 activity. ** p < 0.01. (G) Effect of PFN1 on ROCK2 activity. (H) Flow cytometry measuring changes in the amount of MVs after treatment with Y27632; * p < 0.05.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: Mechanisms underlying the promotion of MLC phosphorylation by PFN1. (A,B) Protein expression after PFN1 overexpression (A) and knockdown (B) measured using western blotting. (C) Protein expression in PFN1 mutants measured using western blotting. (D) PFN1 interactions with ROCK1/2 confirmed using co-IP. (E) Protein expression after treatment with Y27632 (10 µM) measured using western blotting. (F) Effect of PFN1 on ROCK1 activity. ** p < 0.01. (G) Effect of PFN1 on ROCK2 activity. (H) Flow cytometry measuring changes in the amount of MVs after treatment with Y27632; * p < 0.05.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Phospho-proteomics, Expressing, Over Expression, Knockdown, Western Blot, Co-Immunoprecipitation Assay, Activity Assay, Flow Cytometry

ROCK1 inhibitor Y27632 partially reversed the promotion of lung cancer metastasis by PFN1 in vitro and in vivo . (A,B) Wound healing assays conducted to evaluate the effect of Y27632 (A) and Y27632 combined with MVs (B) on cell migration. ** p < 0.01; scale bar, 500 μm. (C) Transwell migration assays conducted to evaluate the effect of Y27632 and Y27632 combined with MVs on cell migration. ** p < 0.01; scale bar, 500 μm. (D) Schematic diagram of the mouse model of metastatic tumor established to determine the effect of Y27632 on PFN1-induced lung cancer metastasis. (E) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing H1299 cells and intraperitoneal injection of Y27632 (10 mg/kg). (F) Representative images of lung and liver metastatic tissue in mice. The number of metastatic nodules is shown in the right-hand side graph. * p < 0.05. (G,H) Representative images of HE-stained lung (G) and liver (H) metastases. (I) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (J) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph; ** p < 0.01.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: ROCK1 inhibitor Y27632 partially reversed the promotion of lung cancer metastasis by PFN1 in vitro and in vivo . (A,B) Wound healing assays conducted to evaluate the effect of Y27632 (A) and Y27632 combined with MVs (B) on cell migration. ** p < 0.01; scale bar, 500 μm. (C) Transwell migration assays conducted to evaluate the effect of Y27632 and Y27632 combined with MVs on cell migration. ** p < 0.01; scale bar, 500 μm. (D) Schematic diagram of the mouse model of metastatic tumor established to determine the effect of Y27632 on PFN1-induced lung cancer metastasis. (E) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing H1299 cells and intraperitoneal injection of Y27632 (10 mg/kg). (F) Representative images of lung and liver metastatic tissue in mice. The number of metastatic nodules is shown in the right-hand side graph. * p < 0.05. (G,H) Representative images of HE-stained lung (G) and liver (H) metastases. (I) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (J) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph; ** p < 0.01.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: In Vitro, In Vivo, Migration, Injection, Staining, Expressing

Schematic diagram of the role of PFN1 in NSCLC metastasis. In the initiation stage of NSCLC, cells with upregulated PFN1 secret more MVs through PFN1 interactions with the ROCK/p-MLC pathway. These MVs contain numerous oncogenenic moleculars, which could enhance migration abilities of PFN1 normal expressed NSCLC cells, and untimately promote progression and metastasis of NSCLC.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: Schematic diagram of the role of PFN1 in NSCLC metastasis. In the initiation stage of NSCLC, cells with upregulated PFN1 secret more MVs through PFN1 interactions with the ROCK/p-MLC pathway. These MVs contain numerous oncogenenic moleculars, which could enhance migration abilities of PFN1 normal expressed NSCLC cells, and untimately promote progression and metastasis of NSCLC.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Migration

Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of ERK, JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled siRNA, JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.

Journal: Journal of Cancer

Article Title: Lycopene upregulates ZO-1 and downregulates claudin-1 through autophagy inhibition in the human cutaneous squamous cell carcinoma cell line COLO-16

doi: 10.7150/jca.26578

Figure Lengend Snippet: Cells were treated with 0, 5, 10 or 20 μM lycopene (a-c). Western blotting analysis was performed to determine the protein levels or phosphorylation of ERK, JNK and p38 MAPK. The protein level of c-jun was determined in COLO-16 cells (a). Cells were treated with or without 10 μM lycopene in the presence or absence of 80 nM rapamycin (d-f), 10 μM SP600125 (g) or 5 μM U0126 (h) for 24 hours. Western blotting analysis was performed to determine the protein levels of ZO-1, claudin-1, JNK and ERK, as well as the phosphorylation of JNK and ERK. In addition, the phosphorylation of MTOR and ribosomal protein S6 was determined in COLO-16 cells (g and h). (i and j): The COLO-16 cells in the control, negative control, RNAi JNK (or ERK) and RNAi JNK (or ERK) plus lycopene groups were treated with transfection agent (Lipofectamine 2000) alone, scrambled siRNA, JNK siRNA (or ERK siRNA) and JNK siRNA (or ERK siRNA) followed by 10 μM lycopene, respectively. The transfection agents were given in the same volume (5 μL) in the control, negative control, RNAi of JNK (or ERK), and RNAi of JNK (or ERK) plus lycopene groups. GAPDH served as a loading control. Representative figures are shown from three independent experiments.

Article Snippet: The scrambled siRNA sequences for ERK (GenePharma) were 5'-UUC UCC GAA CGU GUC ACG UTT-3' (sense) and 5'-ACG UGA CAC GUU CGG AGA ATT-3' (antisense).

Techniques: Western Blot, Phospho-proteomics, Control, Negative Control, Transfection